semaglutide age nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Semaglutide Dosing - Doctor's Advice

Statistical analyses Patients were followed from initiation of the study drugs (after 1 January 2007) until first diagnosis of prostate cancer or other cancer (except non-melanoma skin cancer), emigration, death or 31 December 2019

EWGSOP advocate a primary care assessment combining a questionnaire (SARC-F

take the first step towards a better future now.

However, patients should be aware that these compounded medications are not FDA-approved and may carry risks associated with unverified dosing and quality

Gastroenterology 133, 875886

They may feel that managing the long-term titration, side effects, and mandatory nutritional monitoring required for GLP-1 therapies is best handled by an endocrinologist or primary care physician